NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis.

New investors Atlas Venture, venBio and Versant Ventures joined founding investor Apple Tree Partners as co-leaders in the round, announced Monday. Founded in 2017, Akero emerged from stealth mode with Monday's announcement.

Concurrently, Akero

Read the full 643 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE